Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Anna S. Deal
Factors Associated With Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE)
Advances in Therapy
Medicine
Pharmacology
Related publications
Mirabegron: A Beta-3 Agonist for Overactive Bladder
The Consultant Pharmacist
Overactive Bladder: Symptom or Syndrome?
BJU International
Urology
Mirabegron &Ndash; A Selective &Szlig;3-Adrenoreceptor Agonist for the Treatment of Overactive Bladder
Research and Reports in Urology
Urology
The Effect of Mirabegron, Used for Overactive Bladder Treatment, on Female Sexual Function: A Prospective Controlled Study
BMC Urology
Medicine
Reproductive Medicine
Urology
Pd26-10 Onabotulinumtoxina Provides Early and Consistent Improvements in Overactive Bladder Symptoms and Quality of Life Outcomes in Patients With Overactive Bladder
Journal of Urology
Urology
Mirabegron as Adjuvant Treatment for Patients With Interstitial Cystitis/Bladder Pain Syndrome
Canadian Urological Association Journal
Urology
Perceptions of “Urgency” in Women With Interstitial Cystitis/Bladder Pain Syndrome or Overactive Bladder
Neurourology and Urodynamics
Neurology
Urology
Practical Aspects of Botulinum Toxin-A Treatment in Patients With Overactive Bladder Syndrome
International Neurourology Journal
Neurology
Urology
Complementing Clinical Cancer Registry Data With Patient Reported Outcomes: A Feasibility Study on Routine Electronic Patient‐reported Outcome Assessment for the Austrian Myelome Registry
European Journal of Cancer Care
Oncology
